Day: August 31, 2025

SYDNEY, Aug. 31, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Steven Casey as a Senior Managing Director in its Economic Consulting segment, based in Australia. His arrival strengthens the firm’s public sector and economic advisory capabilities in New South Wales and across Australia. Mr. Casey brings nearly two decades of experience advising federal and state governments, regulators, boards and executives in Australia and internationally. His expertise spans public policy, economics and regulatory reform; public investment strategy; evaluation; advanced analytics, data and AI; technology; policy; service delivery; and large-scale transformation. Based in Sydney, Mr. Casey will support clients with complex fiscal, infrastructure and policy challenges. He also will help drive the national...

MARTINSVILLE, Va., Aug. 31, 2025 (GLOBE NEWSWIRE) — CORRECTED VERSION: On August 29, 2025, the Company issued a press release with an incorrect registration link and this updated release provides the correct link. Corrected release follows in full: Hooker Furnishings Corporation (Nasdaq-GS: HOFT) will present its fiscal 2026 second quarter financial results via teleconference and live internet web cast on Thursday morning, September 11, 2025 at 9:00 AM Eastern Time. A live webcast of the call will be available on the Investor Relations page of the Company’s website at https://investors.hookerfurnishings.com/events and archived for replay. To access the call by phone, participants should go to this link (registration link) and you will be provided with dial-in details. To avoid delays, participants are encouraged to dial into the...

Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%, Consistent with Expected Rates in Prediction Model of Patients with HCM; Simultaneous Publication in Heart Rhythm Longer-Term Data Presented Consistent with Previously Reported Safety Profile of Aficamten Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 31, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, including a pre-specified...

– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity including lipoprotein(a), fibrinogen, and serum amyloid A – NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases, today presented additional data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug in a poster presentation at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain, highlighting...

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Genotypic Status Identified as a Significant Predictor of Risk and Left Ventricular Mass Index May Serve as a Surrogate Marker for Poor Long-Term Outcomes SOUTH SAN FRANCISCO, Calif., Aug. 31, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the presentation of interim data from its ongoing MyClimb™ (ClinicalTrials.gov ID: NCT05112237) natural history study of pediatric participants with MYBPC3-associated...

— Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action — DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and on cellular stress and inflammatory protein expression in endothelial cells and preliminary data showcasing the potential anti-inflammatory mechanism of icosapent ethyl (IPE) via modulation of nod-like receptor protein-3 (NLRP3) inflammasome by monocyte-derived macrophages (MDMs). The data was presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. “These in vitro analyses provide additional insight into the mechanisms of action for VASCEPA/VAZKEPA, including the potential effect of reducing...

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1 Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment1 This study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy® are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments1Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual...

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1 Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment1 This study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy® are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments1Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual...